Equities
  • Price (MXN)892.01
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jan 05 2023 11:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. Its Biologics segment provides development and manufacturing for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene therapies. Its Softgel and Oral Technologies segment provide formulation, development, and manufacturing services for soft capsules, as well as large-scale manufacturing of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. Its Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for, drugs, biologics and clinical trials.

  • Revenue in USD (TTM)4.83bn
  • Net income in USD421.00m
  • Incorporated2007
  • Employees19.00k
  • Location
    Catalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
  • Phone+1 (732) 537-6200
  • Fax+1 (732) 537-6480
  • Websitehttps://www.catalent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CTLT:NYQ since
announced
Transaction
value
Metrics Contract ServicesDeal completed09 Aug 202209 Aug 2022Deal completed-51.25%475.00m
Erytech Pharma SA-Cell Therapy Manufacturing Facility,Princeton,NJDeal completed25 Apr 202225 Apr 2022Deal completed-40.83%44.50m
The Vaccine Manufacturing & Innovation CentreDeal completed18 Feb 202218 Feb 2022Deal completed-45.24%--
Data delayed at least 15 minutes, as of Jan 27 2023 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.